Last reviewed · How we verify
Placebo in combination with Pembrolizumab
Placebo in combination with Pembrolizumab is a PD-1 inhibitor (Pembrolizumab component); Placebo control Small molecule drug developed by Akeso. It is currently in Phase 3 development for Indication under investigation in Phase 3 trial (specific indication not provided).
Placebo serves as a control comparator in a combination study with Pembrolizumab, a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses.
Placebo serves as a control comparator in a combination study with Pembrolizumab, a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses. Used for Indication under investigation in Phase 3 trial (specific indication not provided).
At a glance
| Generic name | Placebo in combination with Pembrolizumab |
|---|---|
| Sponsor | Akeso |
| Drug class | PD-1 inhibitor (Pembrolizumab component); Placebo control |
| Target | PD-1 (Pembrolizumab component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
In this Phase 3 trial design, placebo is administered alongside Pembrolizumab to establish efficacy and safety of the combination regimen. Pembrolizumab works by inhibiting PD-1 on T cells, preventing tumor cells from suppressing immune attack. The placebo arm allows for controlled comparison of the active combination therapy.
Approved indications
- Indication under investigation in Phase 3 trial (specific indication not provided)
Common side effects
- Immune-related adverse events (from Pembrolizumab)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (PHASE3)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (PHASE3)
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo in combination with Pembrolizumab CI brief — competitive landscape report
- Placebo in combination with Pembrolizumab updates RSS · CI watch RSS
- Akeso portfolio CI
Frequently asked questions about Placebo in combination with Pembrolizumab
What is Placebo in combination with Pembrolizumab?
How does Placebo in combination with Pembrolizumab work?
What is Placebo in combination with Pembrolizumab used for?
Who makes Placebo in combination with Pembrolizumab?
What drug class is Placebo in combination with Pembrolizumab in?
What development phase is Placebo in combination with Pembrolizumab in?
What are the side effects of Placebo in combination with Pembrolizumab?
What does Placebo in combination with Pembrolizumab target?
Related
- Drug class: All PD-1 inhibitor (Pembrolizumab component); Placebo control drugs
- Target: All drugs targeting PD-1 (Pembrolizumab component)
- Manufacturer: Akeso — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Indication under investigation in Phase 3 trial (specific indication not provided)
- Compare: Placebo in combination with Pembrolizumab vs similar drugs
- Pricing: Placebo in combination with Pembrolizumab cost, discount & access